Child PTSD Symptom Scale

Study of Non-Invasive Vagus Nerve Stimulation (nVNS) Shows Improvement in PTSD Symptoms and Decreased Inflammatory Response to Stress

Retrieved on: 
Tuesday, August 10, 2021
Post-traumatic stress disorder, Patient, FDA, ECOR, Child PTSD Symptom Scale, Interleukin 6, Naval Information Warfare Center Atlantic, Lists of diseases, Program, Biological Technologies Office (DARPA), DARPA, Disorder, PTSD, User experience, Sexual violence, Emory University, GLOBE, BTO, Spectrum, Woman, Death, NVN, Technology, Georgia Tech, Journal, Georgia Institute of Technology College of Computing, TNT, Man, Manuscript, Meat

Eight million American adults experience PTSD annually, and with limited FDA approved therapies, there is a large unmet medical need.

Key Points: 
  • Eight million American adults experience PTSD annually, and with limited FDA approved therapies, there is a large unmet medical need.
  • The disorder is more prominent in women, with about 10% of women and 4% of men developing PTSD at some point in their lives.
  • The study enrolled twenty patients suffering from PTSD.
  • Study participants were exposed to personalized traumatic scripts followed by an immediate stimulation by an active or sham non-invasive vagus nerve stimulator (nVNS).

Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD

Retrieved on: 
Tuesday, July 6, 2021
Post-traumatic stress disorder, Psychiatry, Psychology, Mind, Adverse childhood experiences, Anxiety disorders, Aftermath of war, Nicotinic antagonists, Clinician Administered PTSD Scale, Psychological trauma, BNC-210, Child PTSD Symptom Scale

The ATTUNE Study is a randomised, double-blind, placebo-controlled, multi-centre Phase 2b clinical trial with a 12-week treatment period.

Key Points: 
  • The ATTUNE Study is a randomised, double-blind, placebo-controlled, multi-centre Phase 2b clinical trial with a 12-week treatment period.
  • The primary objective is to compare BNC210 to placebo on the improvement in PTSD symptom severity as measured by the Clinician Administered PTSD scale for DSM-5 (CAPS-5) following 12 weeks of treatment.
  • An oral tablet formulationof BNC210, showing much improved absorption over the previous liquid suspension formulation, will be evaluated in this study.
  • BNC210 oral tablet formulation is currently being evaluated in a second Phase 2b trial for the treatment of Post-Traumatic Stress Disorder (PTSD) for which it was granted Fast Track designation by the FDA.